Skip to Main Content

Verona Pharma plc

VRNA Real Time Price USD
97.05
+2.98
(3.16%)
As of today at 17:15 UTC-04:00 (Market Closed)
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of VRNA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
VRNA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
VRNA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
VRNA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Whales88New82Increased68Held14Decreased85Closed15

Quarterly net insider trading by VRNA's directors and management

2024Q22024Q32024Q42025Q12025Q2−3.5M−3M−2.5M−2M−1.5M−1M−0.5M0
Net Shares Purchased by Insiders

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

VRNA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
VRNA Income Statement
VRNA Balance Sheet
VRNA Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Particulate composition Mar. 18, 2025
  • Patent Title: Particulate composition Jan. 14, 2025
  • Patent Title: Formulation production process Dec. 17, 2024
  • Patent Title: Treatment Sep. 19, 2023
  • Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 08, 2022
  • Patent Title: Liquid inhalation formulation comprising rpl554 Mar. 16, 2021
  • Patent Title: Treatment Dec. 15, 2020
  • Patent Title: Compound and process Jul. 14, 2020
  • Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Nov. 12, 2019
  • Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 05, 2019
  • Patent Title: Liquid inhalation formulation comprising rpl554 May. 01, 2018
  • Patent Title: Drug combination Aug. 01, 2017
  • Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Jul. 11, 2017
  • Patent Title: Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound Jun. 23, 2015
  • Patent Title: Derivatives of pyrimido[6,1-a]isoquinolin-4-one Aug. 14, 2012
Government Contracts

Estimated quarterly amount awarded from public contracts

20242025−1−0.500.51
Q4Q3Q2Q1Government Contracts Amount
VRNA News

Recent insights relating to VRNA

New Insider Disclosure: Fisher Andrew (General Counsel) disclosed 80000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 400000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 400000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 400000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 400000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Fisher Andrew (General Counsel) disclosed 80000 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Rickard Kathleen A. (Chief Medical Officer) disclosed 114984 shares sold of $VRNAArticle Thumbnail
Verona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025Article Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 587008 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 587008 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Rickard Kathleen A. (Chief Medical Officer) disclosed 49200 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Fisher Andrew (General Counsel) disclosed 26072 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 90360 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Rickard Kathleen A. (Chief Medical Officer) disclosed 34384 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 90360 shares sold of $VRNAArticle Thumbnail
Verona Pharma Reports Q1 2025 Financial Results: $76.3 Million in Revenue Driven by Ohtuvayre® SalesArticle Thumbnail
New Analyst Forecast: $VRNA Given $80.0 Price TargetArticle Thumbnail
Insider Sale: Chief Medical Officer of $VRNA Sells 79,264 SharesArticle Thumbnail
New Insider Disclosure: Rickard Kathleen A. (Chief Medical Officer) disclosed 79264 shares sold of $VRNAArticle Thumbnail
VERONA PHARMA Earnings Results: $VRNA Reports Quarterly EarningsArticle Thumbnail
Verona Pharma Reports Strong Launch Momentum for Ohtuvayre with $36.6 Million in Q4 Sales and Expansion of Clinical ProgramsArticle Thumbnail
Verona Pharma to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025Article Thumbnail
Verona Pharma Reports Approximately $36 Million in Q4 2024 Net Sales for Ohtuvayre with Strong Prescription GrowthArticle Thumbnail
Insider Sale: President and CEO of $VRNA (VRNA) Sells 162,800 SharesArticle Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 881960 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 870672 shares sold of $VRNAArticle Thumbnail
Insider Sale: Chief Financial Officer of $VRNA (VRNA) Sells 12,936 SharesArticle Thumbnail
New Insider Disclosure: ZACCARDELLI DAVID (President and CEO) disclosed 125328 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Hahn Mark W (Chief Financial Officer) disclosed 113240 shares sold of $VRNAArticle Thumbnail
New Insider Disclosure: Rickard Kathleen A. (Chief Medical Officer) disclosed 240000 shares sold of $VRNAArticle Thumbnail
CNBC Recommendations

Recent picks made for VRNA stock on CNBC

PersonalityTypeDate
Jim CramerTrim03/10/2025
Top ETF Holders

ETFs with the largest estimated holdings in VRNA

VRNA Analyst Ratings

VRNA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
VRNA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $VRNA stock a Buy, Sell, or Hold?

  • What is the price target for $VRNA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

VRNA News - TipRanks

Recent insights relating to VRNA from TipRanks

VRNA Top Shareholders
Shareholder
Shares Held
VRNA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $VRNA stock?

  • Who owns the most shares of $VRNA stock?

  • What funds own $VRNA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

VRNA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view VRNA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top